James L Gajewski
Affiliation: Oregon Health and Science University
- Blood and marrow transplantation compensation: perspective in payer and provider relationsJames L Gajewski
Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
Biol Blood Marrow Transplant 10:427-32. 2004..Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy...
- Impending challenges in the hematopoietic stem cell transplantation physician workforceJames L Gajewski
Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon 97239, USA
Biol Blood Marrow Transplant 15:1493-501. 2009....
- A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantationJames L Gajewski
Department of Medicine, Temple University, Philadelphia, PA, USA
Blood 112:3036-47. 2008....
- Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trialRichard T Maziarz
Knight Cancer Institute, Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon Electronic address
Biol Blood Marrow Transplant 21:720-8. 2015..MAPC contribution to blood chimerism was negligible. These phase I data support the safety of stromal stem cell therapy and suggest that MAPC should be tested prospectively as a novel therapeutic option for GVHD prophylaxis after HCT...
- Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantationBaldeep Wirk
Fox Chase Temple University BMT Program, Temple University School of Medicine, 7604 Central Avenue, Philadelphia, PA 19111, USA
Transfusion 48:163-8. 2008..This suggests that donor-recipient Rh mismatching is a risk factor in allogeneic hematopoietic stem cell transplantation and should be a criterion for donor selection...
- Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 yearsEmer O Hanrahan
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
Cancer 106:2327-36. 2006..After a median follow-up of 6.5 years, no significant differences were observed in recurrence-free survival (RFS) or overall survival (OS) between the 2 arms. This report updates the survival analyses...
- The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation servicesJames L Gajewski
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Biol Blood Marrow Transplant 11:871-80. 2005..Details about the individual codes and their approval process are reviewed in this article...
- The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapyYee Chung Cheng
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 10:794-804. 2004..In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting...
- Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 yearsRaymond Wong
Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 102:3052-9. 2003..Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease...
- Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selectionFilippo Montemurro
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 9:330-40. 2003..01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control...
- Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilizationJames L Gajewski
University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
Biol Blood Marrow Transplant 8:550-6. 2002..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...